NYSE:MRK - Merck & Co., Inc. Stock Price, Price Target & More

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc. announced a quarterly dividend on Tuesday, May 22nd. Shareholders of record on Friday, June 15th will be given a dividend of $0.48 per share on Monday, July 9th. This represents a $1.92 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date is Thursday, June 14th. View Merck & Co., Inc.'s Dividend History.

Merck & Co., Inc. declared that its board has approved a stock buyback plan on Saturday, December 2nd 2017, which permits the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company's board believes its shares are undervalued.

Merck & Co., Inc. (NYSE:MRK) issued its earnings results on Tuesday, May, 1st. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.00 by $0.05. The company earned $10.04 billion during the quarter, compared to the consensus estimate of $10.09 billion. Merck & Co., Inc. had a return on equity of 30.93% and a net margin of 4.31%. The firm's revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.88 earnings per share. View Merck & Co., Inc.'s Earnings History.

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Merck & Co., Inc..

Merck & Co., Inc. issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $4.16-4.28 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.19. The company issued revenue guidance of $41.8-43.0 billion, compared to the consensus revenue estimate of $41.86 billion.

18 analysts have issued 12 month target prices for Merck & Co., Inc.'s shares. Their forecasts range from $58.83 to $72.00. On average, they expect Merck & Co., Inc.'s share price to reach $66.0519 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price. View Analyst Ratings for Merck & Co., Inc..

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Merck & Co., Inc. saw a decrease in short interest during the month of June. As of June 29th, there was short interest totalling 17,153,866 shares, a decrease of 21.6% from the June 15th total of 21,867,505 shares. Based on an average daily volume of 11,109,077 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.6% of the shares of the company are sold short. View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Headlines about MRK stock have trended somewhat positive recently, Accern reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Merck & Co., Inc. earned a daily sentiment score of 0.05 on Accern's scale. They also gave media headlines about the company an impact score of 44.85 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Merck & Co., Inc.'s stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.29%), Swedbank (0.15%), Bank of Montreal Can (0.14%), NN Investment Partners Holdings N.V. (0.08%), Manning & Napier Group LLC (0.07%) and Gateway Investment Advisers LLC (0.05%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Manning & Napier Group LLC, Radnor Capital Management LLC, Clinton Group Inc., Fulton Bank N.A., Fjarde AP Fonden Fourth Swedish National Pension Fund, Swedbank and Lodestar Investment Counsel LLC IL. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Julie L Gerberding, Michael J Holston, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

MRK stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Gateway Investment Advisers LLC, LGT Capital Partners LTD., DnB Asset Management AS, Welch & Forbes LLC, Handelsbanken Fonder AB, Sabal Trust CO and Gofen & Glossberg LLC IL. View Insider Buying and Selling for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $62.41.

Merck & Co., Inc. has a market capitalization of $169.56 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]